Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2023 | 4 |
2024 | 1 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1.
Lancet. 2023.
PMID: 37015244
Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators.
Rheault MN, et al.
N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3.
N Engl J Med. 2023.
PMID: 37921461
Clinical Trial.
Item in Clipboard
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators.
Rovin BH, et al.
Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3.
Lancet. 2023.
PMID: 37931634
Clinical Trial.
Item in Clipboard
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D; Cemdisiran Phase 2 Study Investigators and Collaborators.
Barratt J, et al.
Clin J Am Soc Nephrol. 2024 Apr 1;19(4):452-462. doi: 10.2215/CJN.0000000000000384. Epub 2024 Jan 15.
Clin J Am Soc Nephrol. 2024.
PMID: 38214599
Clinical Trial.
Item in Clipboard
Immunological Pattern in IgA Nephropathy.
Esteve Cols C, Graterol Torres FA, Quirant Sánchez B, Marco Rusiñol H, Navarro Díaz MI, Ara Del Rey J, Martínez Cáceres EM.
Esteve Cols C, et al. Among authors: marco rusinol h.
Int J Mol Sci. 2020 Feb 18;21(4):1389. doi: 10.3390/ijms21041389.
Int J Mol Sci. 2020.
PMID: 32085673
Free PMC article.
Item in Clipboard
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA; ADVOCATE Study Group.
Strand V, et al.
Lancet Rheumatol. 2023 Aug;5(8):e451-e460. doi: 10.1016/S2665-9913(23)00092-9. Epub 2023 Jul 24.
Lancet Rheumatol. 2023.
PMID: 38251577
Clinical Trial.
Item in Clipboard
Cite
Cite